Executive Moves
- • By
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
- • By
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
- • By
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
- • By
<p>Executive Summary </p> <br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>
- • By
<p>Executive Summary </p> <br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>
- • By
In this week's podcast edition of Five Must-Know Things: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.
- • By
Recent moves in the industry include C-suite shuffle at Perspective Therapeutics and Bausch Health, plus Oculis Holding gets a new CDO and Tiziana Life Sciences gets a new CEO.
- • By
Recent moves in the industry include changes at the top for Xilio Therapeutics, Zentalis Pharmaceuticals, Beam Therapeutics and Cipher Pharmaceuticals, plus Ardelyx gets a new chief commercial officer.
- • By
Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.
- • By
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
- • By
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
- • By
Recent moves in the industry include C-suite shuffles at Valeo Pharma, Xeris Biopharma, ALX Oncology and MEI Pharma, plus BeiGene and Phio Pharmaceuticals get new chief financial officers.
- • By
Recent moves in the industry include C-suite shuffle at Nkarta, plus I-Mab gets a new CEO.
- • By
Despite initial promise, a novel autologous cell transplant therapy for severe heart failure has faced multiple challenges in gaining full approval in Japan, potentially providing learnings for other developers of regenerative medicines.
- • By
Recent moves in the industry include C-suite shuffles at Pulmatrix, Intellia Therapeutics and BridgeBio, while Akeso got a new chief financial officer from Cellectis.
- • By
Recent moves in the industry include C-suite shuffles at AbbVie, Abivax and Ikena Oncology, plus I-Mab.
- • By
In this week's podcast edition of Five Must-Know Things: Q1’s top 10 drugs; Pfizer’s R&D leadership succession; Lilly bolsters IBD pipeline; first half deal volume up but value down; and EU firms’ China sentiment plummets.
- • By
Recent moves in the industry include C-suite shuffle at Armis Biopharma, plus Voyager Therapeutics acquires chief financial officer from Vor Biopharma.
- • By
Recent moves in the industry include changes at the top at AbbVie, Regenxbio and Keros Therapeutics, plus Merus acquires a chief medical officer from ImmunoGen. Y-mAbs Therapeutics hires a chief financial officer from Voyager Therapeutics.











